
{
    "Variants Include": [
        {
            "Gene": "SNCA",
            "variants": [
                {
                    "HGVS": "NM_000345.4:c.88G>C",
                    "cDNA Change": {
                        "transcript": "NM_000345.4",
                        "ref": "G",
                        "alt": "C",
                        "position": "88"
                    },
                    "Protein Change": {
                        "ref": "A",
                        "alt": "P",
                        "position": "30"
                    },
                    "Description in input context": "A30P"
                },
                {
                    "HGVS": "NM_000345.4:c.157G>A",
                    "cDNA Change": {
                        "transcript": "NM_000345.4",
                        "ref": "G",
                        "alt": "A",
                        "position": "157"
                    },
                    "Protein Change": {
                        "ref": "A",
                        "alt": "T",
                        "position": "53"
                    },
                    "Description in input context": "A53T"
                }
            ]
        }
    ],
    "Described Disease": {
        "Described Disease": "Parkinson's disease",
        "MONDO": "MONDO:0005180"
    },
    "Experiment Method": [
        {
            "Assay Method": "hPLD2 activity assay",
            "Material used": {
                "Material Source": "Recombinant protein",
                "Material Name": "hPLD2, synucleins",
                "Description": "hPLD2 activity was assayed as described. Briefly, 0.1 nM hPLD2 (1 ng) was added to assay buffer (50 mM Na-Hepes (pH 7.5), 3 mM EGTA, 80 mM KCl, 1 mM DTT, 3 mM MgCl₂, 2 mM CaCl₂) containing lipid vesicles (phosphatidylethanolamine (PE), phosphoinositol 4,5-bisphosphate (PI(4,5)P₂), and phosphatidylcholine (PC) (Avanti Polar Lipids) molar ratio 16:1.4:1, plus 50,000 - 100,000 cpm [³H]phosphatidylcholine (Amersham-Pharmacia)) at a final lipid concentration of 100 μM in a total volume of 100 μl. Synucleins were added where indicated. Reactions were incubated at 37 °C for 30 minutes and then stopped with 200 μl of 10% (v/v) trichloroacetic acid and 100 μl of 10% (w/v) BSA to precipitate proteins and lipids. Free [³H]choline released by hPLD2 was measured by scintillation counting."
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_000345.4:c.88G>C",
                    "Conclusion": "Normal",
                    "Molecular Effect": "No Effect",
                    "Result Description": "A30P inhibition was not different from wild-type."
                },
                {
                    "Variant": "NM_000345.4:c.157G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "gain-of-function",
                    "Result Description": "The A53T mutant had a greater inhibitory effect compared to wild-type α-synuclein."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "Yes",
                "Description": "Means ± SD for three or four separate experiments are shown."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "Wild-type hAS"
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "Statistical analysis of inhibition used the General Linear Model to perform analysis of covariates (ANCOVA) to compare slopes between proteins."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D.",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "N.D.",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        }
    ]
}